文献速递骨质疏松与代谢性骨病创伤骨科

类风湿关节炎中的骨质疏松:危险因素与临床预测模型的新视角

Osteoporosis in rheumatoid arthritis: a new perspective on risk factors and clinical prediction models.
PubMed 文献 · Osteoporos Int · 2026-04-28

本综述聚焦类风湿关节炎(RA)合并骨质疏松(OP)的多维风险网络,并评估现有临床预测模型(CPM)的开发、性能与适用性。文章指出多数CPM受限于样本量小、外部验证不足和临床可转化性欠佳,且当前范式偏重诊断而非预后。未来需提升方法学严谨性与泛化性,扩展预测范围至未来OP和骨折风险,并开发融入疾病特异病理生理的RA专用骨折预测工具,以FRAX等成熟工具为基准进行严格评测。

要点

  • RA合并OP显著增加骨折负担,但OP筛查常被延迟,存在未满足的临床需求。
  • 现有CPM从基础算法演进至整合生物标志物的复杂算法,但仍受样本量小、外部验证不足和临床可转化性欠佳限制。
  • 当前范式偏重诊断而非预后,未来需开发RA专用骨折预测工具并以FRAX为基准严格评测。

核心结论

  • 现有RA-OP临床预测模型虽从基础演进至整合生物标志物的复杂算法,但多数受限于样本量小、外部验证不足和临床可转化性欠佳。
  • 当前范式偏重诊断而非预后,未来需提升方法学严谨性与泛化性,扩展预测范围至未来OP和骨折风险。
  • 应开发融入疾病特异病理生理的RA专用骨折预测工具,并以FRAX等成熟工具为基准进行严格评测。

研究设计与样本

  • 本文为综述,旨在整合RA-OP危险因素并评估现有临床预测模型的开发、性能与适用性。

主要发现

  • RA-OP存在多维风险网络,早期检测至关重要但筛查常延迟。
  • 现有CPM从基础算法演进至整合生物标志物的复杂算法,但多数受限于样本量小、外部验证不足和临床可转化性欠佳。
  • 当前范式偏重诊断而非预后。

临床怎么用

  • 临床应重视RA患者的OP早期风险分层,不应延迟筛查。
  • 现有CPM可用于早期风险分层,但需警惕其样本量小、外部验证不足和临床可转化性欠佳的限制。
  • 未来可期待RA专用骨折预测工具,以FRAX为基准评测,推动更主动和个体化的预防。

局限性

  • 多数CPM受限于样本量小、外部验证不足和临床可转化性欠佳。
  • 当前范式偏重诊断而非预后,预测范围未充分涵盖未来OP和骨折风险。
  • 缺乏融入疾病特异病理生理的RA专用骨折预测工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis (OP) is a prevalent and serious comorbidity in rheumatoid arthritis (RA), significantly increasing the fracture burden. Although early detection is crucial, OP screening in RA is often delayed, representing an unmet clinical need. Clinical prediction models (CPMs) offer a solution for early risk stratification, yet a synthesis that integrates RA-OP risk factors and evaluates existing CPMs is lacking. This review addresses this gap by delineating the multidimensional risk network for RA-OP and evaluating the development, performance, and applicability of current CPMs. We find that despite evolution from basic to sophisticated biomarker-integrated algorithms, most CPMs are constrained by modest sample sizes, insufficient external validation, and suboptimal clinical translatability. The current paradigm focuses predominantly on diagnosis rather than prognosis. To address these limitations, future research should aim to enhance the methodological rigor and generalizability of models, expand their predictive scope to encompass future risk of OP and fractures, and develop RA-specific fracture prediction tools that incorporate disease-specific pathophysiology, with performance rigorously benchmarked against established tools such as the fracture risk assessment tool (FRAX). Progress along these lines may help shift the management paradigm toward more proactive and personalized prevention, with the potential to improve long-term skeletal health outcomes in RA.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Shao Y, Yang X, Shi Q, et al. Osteoporosis in rheumatoid arthritis: a new perspective on risk factors and clinical prediction models. Osteoporos Int. 2026. PMID: 42049891. doi:10.1007/s00198-026-08059-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。